| Literature DB >> 30001781 |
Blas Y Betancourt1, Ann Biehl2, James D Katz3, Ananta Subedi3.
Abstract
Providing safe and effective pharmacotherapy to geriatric patients with rheumatologic disorders is challenging. Multidisciplinary care involving rheumatologists, primary care physicians, and other specialties can optimize benefit and reduce adverse outcomes. Oral disease-modifying antirheumatic drugs, including methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and the small molecule inhibitors tofacitinib and apremilast have distinctive monitoring requirements and specific adverse reaction profiles. This article provides clinically relevant pearls for use of these interventions in older patients. Published by Elsevier Inc.Entities:
Keywords: Apremilast; DMARDs; Geriatrics; Rheumatoid arthritis; Rheumatology; Tofacitinib
Mesh:
Substances:
Year: 2018 PMID: 30001781 PMCID: PMC6047536 DOI: 10.1016/j.rdc.2018.03.010
Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN: 0889-857X Impact factor: 2.670